Skip to main content
Caplight Logo









Aerska

Aerska

Private
DublinHealthcare & Life Scienceshttps://www.aerska.com/

Last Round

Series A

May 20, 2026

Total Funding Raised

$119M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Aerska is a biotechnology company developing RNA interference (RNAi) medicines designed to treat, delay, and prevent diseases of the brain.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

RNA interferenceRNAi therapyblood-brain barrier deliveryAntibody-Oligonucleotide ConjugateAOC platformgene silencingbrain shuttleCNS drug deliveryneurological disease therapyoligonucleotide therapeuticsgenetic medicinedrug delivery platformAlzheimer's diseaseParkinson's diseasebiopharma partnerships

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Aerska Comparables

Compare Aerska with similar companies based on industry and business-model similarity.

Aerska comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cenos Therapeutics
87%
CereCura Nanotherapeutics
80%
Qinotto, Inc.
79%

Aerska Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 20, 2026
Series AFeb 9, 2026
SeedOct 2, 2025

Aerska Investors

Notable investors and investment history

Aerska investors
InvestorRounds
Iaso VenturesSeries A
Backed VCSeed
Saras CapitalSeed
LingottoSeed
BlueYard CapitalSeed
Ada VenturesSeed
age1Series A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 18, 2026

    Grew 27% QoQ, from 22 to 28 employees.

  • Jun 25, 2026

    Grew 35% QoQ, from 20 to 27 employees.

Recent news

Latest coverage and updates

  • hiresSep 17, 2026

    Aerska, Inc. hired Laura Sepp-Lorenzino as Scientific Advisory Board on Sep 17th '26.

Aerska Filings

Explore SEC and related filing metadata, where available.

Aerska filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Aerska's valuation, stock price, and market status.

Is Aerska a public or private company?

Aerska is a private company.

What is the current stock price of Aerska?

Aerska is a private company with no public stock price. No recent secondary market data is available.

How much is Aerska worth (valuation)?

Valuation information for Aerska is not publicly available.

Can I buy Aerska stock?

Aerska shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Aerska's last funding round?

Aerska's most recent funding round was Series A on February 9, 2026.

Who are the main investors in Aerska?

Key investors in Aerska include Backed VC, age1, Speedinvest, LSP Dementia Fund.

Will Aerska IPO soon?

No public IPO plans have been announced for Aerska.

How can I track Aerska secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Aerska's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersDublin
Employee Range26
Year Founded2025
Last FundingMay 20, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?